IN2014MN00842A - - Google Patents

Info

Publication number
IN2014MN00842A
IN2014MN00842A IN842MUN2014A IN2014MN00842A IN 2014MN00842 A IN2014MN00842 A IN 2014MN00842A IN 842MUN2014 A IN842MUN2014 A IN 842MUN2014A IN 2014MN00842 A IN2014MN00842 A IN 2014MN00842A
Authority
IN
India
Prior art keywords
methods
icotinib
pollutants
intermediates
economy
Prior art date
Application number
Inventor
Shaojing Hu
Wei Long
Fei Wang
Zongquan Li
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of IN2014MN00842A publication Critical patent/IN2014MN00842A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D325/00—Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups C07D303/00 - C07D323/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to the technical field of medicine. Provided are methods of preparing icotinib icotinib hydrochloride and intermediates thereof. The methods avoid the use of phosphoryl chloride thereby greatly reducing the emission of pollutants which is of major benefit to the economy and environment.
IN842MUN2014 2011-10-31 2012-12-28 IN2014MN00842A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011081586 2011-10-31
PCT/CN2012/087802 WO2013064128A1 (en) 2011-10-31 2012-12-28 Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof

Publications (1)

Publication Number Publication Date
IN2014MN00842A true IN2014MN00842A (en) 2015-07-03

Family

ID=48191387

Family Applications (1)

Application Number Title Priority Date Filing Date
IN842MUN2014 IN2014MN00842A (en) 2011-10-31 2012-12-28

Country Status (12)

Country Link
US (1) US9085588B2 (en)
EP (1) EP2796461B1 (en)
CN (2) CN105237510A (en)
AU (1) AU2012331547C1 (en)
BR (1) BR112014010479A2 (en)
CA (1) CA2854083C (en)
ES (1) ES2641953T3 (en)
HK (1) HK1213894A1 (en)
IN (1) IN2014MN00842A (en)
SG (1) SG11201401953WA (en)
WO (1) WO2013064128A1 (en)
ZA (1) ZA201403858B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010479A2 (en) * 2011-10-31 2017-04-25 Betta Pharmaceuticals Co Ltd compound, method for preparing a compound, method for preparing icotinib from a compound and method for preparing icotinib hydrochloride from a compound
CN104487443B (en) * 2013-06-09 2016-03-23 贝达药业股份有限公司 Crystal formation of Conmana maleate and uses thereof
EP3007700B1 (en) * 2013-06-09 2017-06-28 Betta Pharmaceuticals Co., Ltd. New polymorphic forms of icotinib phosphate and uses thereof
CN104470929B (en) * 2013-06-09 2018-11-30 贝达药业股份有限公司 The crystal form of Conmana and its application
CN104470526B (en) * 2013-06-09 2016-07-13 贝达药业股份有限公司 Phosphatic crystal formation of Conmana and application thereof
JP6518655B2 (en) * 2013-06-09 2019-05-22 ベータ ファーマシューティカルズ カンパニー リミテッド Polymorphs of icotinib maleate and use thereof
CA2914857C (en) 2013-06-09 2017-08-22 Betta Pharmaceuticals Co., Ltd Polymorphic forms of icotinib and uses thereof
CN103724376A (en) * 2013-12-31 2014-04-16 同济大学 Novel latent antitumor drug platinum complex and preparation method thereof
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN114980883A (en) 2020-01-20 2022-08-30 阿斯利康(瑞典)有限公司 Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN111763214B (en) * 2020-08-10 2022-03-15 苏州富士莱医药股份有限公司 Preparation method of icotinib
CN114276324A (en) * 2021-12-31 2022-04-05 浙江拓普药业股份有限公司 Preparation method and application of icotinib intermediate
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078409B2 (en) * 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
CN1305468C (en) 2003-05-29 2007-03-21 中国人民解放军第三○二医院 Bolengsu compound and its prepn, medicine composition and use
WO2007138613A2 (en) * 2006-05-25 2007-12-06 Vittal Mallya Scientific Research Foundation A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride
CN104530061B (en) 2008-07-08 2017-05-10 贝达药业股份有限公司 Icotinib hydrochloride crystal forms, medicine composition and application of icotinib hydrochloride crystal forms
KR101538707B1 (en) * 2010-07-14 2015-07-22 베타 파머수티컬 컴퍼니 리미티드 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
BR112014010479A2 (en) * 2011-10-31 2017-04-25 Betta Pharmaceuticals Co Ltd compound, method for preparing a compound, method for preparing icotinib from a compound and method for preparing icotinib hydrochloride from a compound

Also Published As

Publication number Publication date
EP2796461A4 (en) 2015-05-27
ES2641953T3 (en) 2017-11-14
WO2013064128A1 (en) 2013-05-10
AU2012331547B2 (en) 2015-07-16
CA2854083C (en) 2016-12-13
CA2854083A1 (en) 2013-05-10
ZA201403858B (en) 2015-12-23
US9085588B2 (en) 2015-07-21
AU2012331547A1 (en) 2014-05-29
HK1213894A1 (en) 2016-07-15
AU2012331547C1 (en) 2016-04-21
SG11201401953WA (en) 2014-09-26
RU2014121337A (en) 2015-12-10
BR112014010479A2 (en) 2017-04-25
CN105237510A (en) 2016-01-13
CN104024262B (en) 2017-03-22
US20140343283A1 (en) 2014-11-20
CN104024262A (en) 2014-09-03
EP2796461A1 (en) 2014-10-29
EP2796461B1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
IN2014MN00842A (en)
CY1123958T1 (en) METHOD OF PREPARATION OF CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES
CO7121320A2 (en) Anti-hla-b * 27 antibodies and uses of these
EA201491224A1 (en) ANTI-PSF-TAU-ANTIBODIES AND THEIR APPLICATION
BR112014026926A2 (en) therapeutic use of chardonnay seed products
UA110354C2 (en) Anti-viral compounds
TWD169280S (en) Air purifier
TWD169282S (en) Air purifier
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP2982742A4 (en) Photobioreactor for mass culturing of photosynthetic microorganism
UA115231C2 (en) Imidazohyrrolidinone compounds
EP2827869A4 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
TWD169281S (en) Air purifier
EA201390274A1 (en) Boron-containing small molecules
NZ704039A (en) Cell-free dna as a therapeutic target for female infertility and diagnostic marker
BR112014007029A2 (en) improved methods of gene therapy
UY34343A (en) PROTEINS OF UNION TO THE ANTIGEN CD27L
MX360188B (en) Substituted biaryl alkyl amides.
MX339533B (en) Dac hyp compositions and methods.
UY34287A (en) UNIVERSAL PROTECTOR OF ROSCAS DE CAÑOS
MX2013015308A (en) Proteasome inhibitors and processes for their preparation, purification and use.
IN2012MU03723A (en)
GB2518813A (en) OMV vaccine against Burkholderia infections
IN2014KN01491A (en)
EA201400165A1 (en) PARTICLES BASED ON POLYACRYLATE THAT CONTAIN AN ACTIVE CONNECTION